GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » 1-Year Share Buyback Ratio

GTHP (Guided Therapeutics) 1-Year Share Buyback Ratio : -20.40% (As of Dec. 2024 )


View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Guided Therapeutics's current 1-Year Share Buyback Ratio was -20.40%.

GTHP's 1-Year Share Buyback Ratio is ranked worse than
73.43% of 572 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs GTHP: -20.40

Competitive Comparison of Guided Therapeutics's 1-Year Share Buyback Ratio

For the Medical Devices subindustry, Guided Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guided Therapeutics's 1-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's 1-Year Share Buyback Ratio falls into.


;
;

Guided Therapeutics 1-Year Share Buyback Ratio Calculation

Guided Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2023 ) - Shares Outstanding (EOP) (Dec. 2024 )) / Shares Outstanding (EOP) (Dec. 2023 )
=(54.105 - 65.131) / 54.105
=-20.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics  (OTCPK:GTHP) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Guided Therapeutics 1-Year Share Buyback Ratio Related Terms

Guided Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » 1-Year Share Buyback Ratio
Comparable Companies
FOFA SINT NUMD WOK AEMD TNON AIMD STME AMIX ADMT ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Website
https://www.guidedinc.com
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
Michael C James director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
John E Imhoff director, 10 percent owner P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic director 349 FORBES AVE, SAN RAFAEL CA 94901
Richard P. Blumberg director 2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff 10 percent owner 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright officer: Chief Executive Officer 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp. 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock director 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff director C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen director P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot officer: VP of R & D 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071